Canagliflozin
Encyclopedia
Canagliflozin is an experimental drug being developed by Johnson & Johnson
for the treatment of type 2 diabetes. It is an inhibitor
of subtype 2 sodium-glucose transport protein
(SGLT2), which is responsible for at least 90% of the glucose reabsorption
in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.
Johnson & Johnson
Johnson & Johnson is an American multinational pharmaceutical, medical devices and consumer packaged goods manufacturer founded in 1886. Its common stock is a component of the Dow Jones Industrial Average and the company is listed among the Fortune 500....
for the treatment of type 2 diabetes. It is an inhibitor
Enzyme inhibitor
An enzyme inhibitor is a molecule that binds to enzymes and decreases their activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. They are also used as herbicides and pesticides...
of subtype 2 sodium-glucose transport protein
Sodium-glucose transport proteins
Sodium-dependent glucose cotransporters are a family of glucose transporter found in the intestinal mucosa of the small intestine and the proximal tubule of the nephron . They contribute to renal glucose reabsorption...
(SGLT2), which is responsible for at least 90% of the glucose reabsorption
Reabsorption
In physiology, reabsorption or tubular reabsorption is the flow of glomerular filtrate from the proximal tubule of the nephron into the peritubular capillaries, or from the urine into the blood...
in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.